mp.weixin.qq.com·· 3 hours agoPickScore78
Iza-bren PANKU-Lung01 Hits PFS Primary Endpoint in EGFR-TKI-Resistant NSCLC; Su Chunxia Discusses Later-Line Positioning
In brief
The Phase III PANKU-Lung01 trial of iza-bren (BL-B01D1) met its primary PFS endpoint in advanced NSCLC resistant to EGFR-TKIs and was selected as an LBA at the 2026 ESMO Congress, with data due on the 26th. Historical platinum-based doublet chemotherapy achieved an ORR of about 30% and median PFS of 4 to 5 months, while the cited Phase II monotherapy data for iza-bren showed an ORR of 66.0% and median PFS of 12.5 months.
Why it matters
Compares the PANKU-Lung01 primary endpoint with platinum chemotherapy historical data and Phase II monotherapy results to support the later-line bispecific ADC strategy.
Source: mp.weixin.qq.com · mp.weixin.qq.com